Skip to main content
SpringerLink
Log in
Book cover

Dermatoanthropology of Ethnic Skin and Hair pp 417–436Cite as

Treatment Strategies for Hyperpigmentation

  • Chapter
  • First Online:

Abstract

Disorders of hyperpigmentation commonly afflict the ethnic population. Given current immigration trends, dyschromias are poised to become a condition increasingly encountered by clinicians. Developing a strong understanding of treatment options and associated side effects is essential. This chapter will focus on the treatment hierarchy of the most common acquired disorders of hyperpigmentation (i.e., melasma, post-inflammatory hyperpigmentation): (i) topical hypopigmenting agents, (ii) chemical peels, and (iii) oral agents, microdermabrasion, microneedling, and laser therapy. In addition to discussing the advantages and disadvantages of these therapies, it will provide a brief overview of emerging treatment options.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Alexis AF, Sergay AB, Taylor SC. Common dermatologic disorders in skin of color: a comparative practice survey. Cutis. 2007;80(5):387–94.

    PubMed  Google Scholar 

  2. Day J. Population projection of the US by age, sex, race, and Hispanic origin: 1995–2050, US Bureau of Census, Current Population Report. Washington, DC: US Government Printing Office; 1996. p. 25–1130.

    Google Scholar 

  3. Desai SR. Hyperpigmentation therapy: a review. J Clin Aesthet Dermatol. 2014;7(8):13–7.

    PubMed  PubMed Central  Google Scholar 

  4. Lynde CB, Kraft JN, Lynde CW. Topical treatments for melasma and postinflammatory hyperpigmentation. Skin Therapy Lett. 2006;11(9):1–6.

    CAS  PubMed  Google Scholar 

  5. Grimes PE, Yamada N, Bhawan J. Light microscopic, immunohistochemical, and ultrastructural alterations in patients with melasma. Am J Dermatopathol. 2005;27(2):96–101.

    Article  PubMed  Google Scholar 

  6. Wang SQ, Lim HW. Current status of the sunscreen regulation in the United States: 2011 Food and Drug Administration’s final rule on labeling and effectiveness testing. J Am Acad Dermatol. 2011;65(4):863–9.

    Article  PubMed  Google Scholar 

  7. Agbai ON, Buster K, Sanchez M, Hernandez C, Kundu RV, Chiu M, et al. Skin cancer and photoprotection in people of color: a review and recommendations for physicians and the public. J Am Acad Dermatol. 2014;70(4):748–62.

    Article  PubMed  Google Scholar 

  8. Nesby-O’Dell S, Scanlon KS, Cogswell ME, Gillespie C, Hollis BW, Looker AC, et al. Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: third National Health and Nutrition Examination Survey, 1988–1994. Am J Clin Nutr. 2002;76(1):187–92.

    PubMed  Google Scholar 

  9. Azurdia RM, Pagliaro JA, Diffey BL, Rhodes LE. Sunscreen application by photosensitive patients is inadequate for protection. Br J Dermatol. 1999;140(2):255–8.

    Article  CAS  PubMed  Google Scholar 

  10. Sambandan DR, Ratner D. Sunscreens: an overview and update. J Am Acad Dermatol. 2011;64(4):748–58.

    Article  CAS  PubMed  Google Scholar 

  11. Diffey B. Sunscreens: expectation and realization. Photodermatol Photoimmunol Photomed. 2009;25(5):233–6.

    Article  PubMed  Google Scholar 

  12. Wolf R, Tüzün B, Tüzün Y. Sunscreens. Dermatol Ther. 2001;14(3):208–14.

    Article  Google Scholar 

  13. Kullavanijaya P, Lim HW. Photoprotection. J Am Acad Dermatol. 2005;52(6):937–58.

    Article  PubMed  Google Scholar 

  14. Stark KEG. Method for creating custom blended cosmetics. Google Patents; 2009.

    Google Scholar 

  15. Castanedo-Cazares JP, Hernandez-Blanco D, Carlos-Ortega B, Fuentes-Ahumada C, Torres-Álvarez B. Near-visible light and UV photoprotection in the treatment of melasma: a double-blind randomized trial. Photodermatol Photoimmunol Photomed. 2014;30(1):35–42.

    Article  CAS  PubMed  Google Scholar 

  16. Vashi NA, Kundu RV. Facial hyperpigmentation: causes and treatment. Br J Dermatol. 2013;169(Suppl 3):41–56.

    Article  PubMed  Google Scholar 

  17. Palumbo A, d’Ischia M, Misuraca G, Prota G. Mechanism of inhibition of melanogenesis by hydroquinone. Biochim Biophys Acta. 1991;1073(1):85–90.

    Article  CAS  PubMed  Google Scholar 

  18. Jimbow K, Obata H, Pathak MA, Fitzpatrick TB. Mechanism of depigmentation by hydroquinone. J Invest Dermatol. 1974;62(4):436–49.

    Article  CAS  PubMed  Google Scholar 

  19. Grimes PE. Management of hyperpigmentation in darker racial ethnic groups. Semin Cutan Med Surg. 2009;28(2):77–85.

    Article  CAS  PubMed  Google Scholar 

  20. Levin CY, Maibach H. Exogenous ochronosis. An update on clinical features, causative agents and treatment options. Am J Clin Dermatol. 2001;2(4):213–7.

    Article  CAS  PubMed  Google Scholar 

  21. Haddad AL, Matos LF, Brunstein F, Ferreira LM, Silva A, Costa D Jr. A clinical, prospective, randomized, double-blind trial comparing skin whitening complex with hydroquinone vs. placebo in the treatment of melasma. Int J Dermatol. 2003;42(2):153–6.

    Article  CAS  PubMed  Google Scholar 

  22. Ortonne JP. Retinoid therapy of pigmentary disorders. Dermatol Ther. 2006;19(5):280–8.

    Article  PubMed  Google Scholar 

  23. Bikowski J. Mechanisms of the comedolytic and anti-inflammatory properties of topical retinoids. J Drugs Derm. 2004;4(1):41–7.

    Google Scholar 

  24. Dogra S, Kanwar AJ, Parsad D. Adapalene in the treatment of melasma: a preliminary report. J Dermatol. 2002;29(8):539–40.

    Article  PubMed  Google Scholar 

  25. Bulengo-Ransby SM, Griffiths CE, Kimbrough-Green CK, Finkel LJ, Hamilton TA, Ellis CN, et al. Topical tretinoin (retinoic acid) therapy for hyperpigmented lesions caused by inflammation of the skin in black patients. N Engl J Med. 1993;328(20):1438–43.

    Article  CAS  PubMed  Google Scholar 

  26. Griffiths CE, Finkel LJ, Ditre CM, Hamilton TA, Ellis CN, Voorhees JJ. Topical tretinoin (retinoic acid) improves melasma. A vehicle-controlled, clinical trial. Br J Dermatol. 1993;129(4):415–21.

    Article  CAS  PubMed  Google Scholar 

  27. Fleckman P. Management of the ichthyoses. Skin Therapy Lett. 2003;8(6):3–7.

    CAS  PubMed  Google Scholar 

  28. Chan R, Park KC, Lee MH, Lee ES, Chang SE, Leow YH, et al. A randomized controlled trial of the efficacy and safety of a fixed triple combination (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) compared with hydroquinone 4% cream in Asian patients with moderate to severe melasma. Br J Dermatol. 2008;159(3):697–703.

    CAS  PubMed  Google Scholar 

  29. Grimes P, Kelly AP, Torok H, Willis I. Community-based trial of a triple-combination agent for the treatment of facial melasma. Cutis. 2006;77(3):177–84.

    PubMed  Google Scholar 

  30. Cayce KA, McMichael AJ, Feldman SR. Hyperpigmentation: an overview of the common afflictions. Dermatol Nurs. 2004;16(5):401–6, 13–6; quiz 17.

    Google Scholar 

  31. Torok H, Taylor S, Baumann L, Jones T, Wieder J, Lowe N, et al. A large 12-month extension study of an 8-week trial to evaluate the safety and efficacy of triple combination (TC) cream in melasma patients previously treated with TC cream or one of its dyads. J Drugs Derm. 2005;4(5):592–7.

    Google Scholar 

  32. Fitton A, Goa KL. Azelaic acid. A review of its pharmacological properties and therapeutic efficacy in acne and hyperpigmentary skin disorders. Drugs. 1991;41(5):780–98.

    Article  CAS  PubMed  Google Scholar 

  33. Draelos ZD. Skin lightening preparations and the hydroquinone controversy. Dermatol Ther. 2007;20(5):308–13.

    Article  PubMed  Google Scholar 

  34. Fleischer AB Jr, Schwartzel EH, Colby SI, Altman DJ. The combination of 2% 4-hydroxyanisole (Mequinol) and 0.01% tretinoin is effective in improving the appearance of solar lentigines and related hyperpigmented lesions in two double-blind multicenter clinical studies. J Am Acad Dermatol. 2000;42(3):459–67.

    Article  PubMed  Google Scholar 

  35. Ortonne JP, Passeron T. Melanin pigmentary disorders: treatment update. Dermatol Clin. 2005;23(2):209–26.

    Article  PubMed  Google Scholar 

  36. Garcia A, Fulton JE Jr. The combination of glycolic acid and hydroquinone or kojic acid for the treatment of melasma and related conditions. Dermatol Surg. 1996;22(5):443–7.

    Article  CAS  PubMed  Google Scholar 

  37. Nakagawa M, Kawai K, Kawai K. Contact allergy to kojic acid in skin care products. Contact Dermatitis. 1995;32(1):9–13.

    Article  CAS  PubMed  Google Scholar 

  38. Yokota T, Nishio H, Kubota Y, Mizoguchi M. The inhibitory effect of glabridin from licorice extracts on melanogenesis and inflammation. Pigment Cell Res. 1998;11(6):355–61.

    Article  CAS  PubMed  Google Scholar 

  39. Fu B, Li H, Wang X, Lee FS, Cui S. Isolation and identification of flavonoids in licorice and a study of their inhibitory effects on tyrosinase. J Agric Food Chem. 2005;53(19):7408–14.

    Article  CAS  PubMed  Google Scholar 

  40. Amer M, Metwalli M. Topical liquiritin improves melasma. Int J Dermatol. 2000;39(4):299–301.

    Article  CAS  PubMed  Google Scholar 

  41. Boissy RE, Visscher M, DeLong MA. DeoxyArbutin: a novel reversible tyrosinase inhibitor with effective in vivo skin lightening potency. Exp Dermatol. 2005;14(8):601–8.

    Article  CAS  PubMed  Google Scholar 

  42. Maeda K, Fukuda M. Arbutin: mechanism of its depigmenting action in human melanocyte culture. J Pharmacol Exp Ther. 1996;276(2):765–9.

    CAS  PubMed  Google Scholar 

  43. Davis EC, Callender VD. Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color. J Clin Aesthet Dermatol. 2010;3(7):20–31.

    PubMed  PubMed Central  Google Scholar 

  44. Carcamo JM, Pedraza A, Borquez-Ojeda O, Golde DW. Vitamin C suppresses TNF alpha-induced NF kappa B activation by inhibiting I kappa B alpha phosphorylation. Biochemistry. 2002;41(43):12995–3002.

    Article  CAS  PubMed  Google Scholar 

  45. Darr D, Combs S, Dunston S, Manning T, Pinnell S. Topical vitamin C protects porcine skin from ultraviolet radiation-induced damage. Br J Dermatol. 1992;127(3):247–53.

    Article  CAS  PubMed  Google Scholar 

  46. Espinal-Perez LE, Moncada B, Castanedo-Cazares JP. A double-blind randomized trial of 5% ascorbic acid vs. 4% hydroquinone in melasma. Int J Dermatol. 2004;43(8):604–7.

    Google Scholar 

  47. Paine C, Sharlow E, Liebel F, Eisinger M, Shapiro S, Seiberg M. An alternative approach to depigmentation by soybean extracts via inhibition of the PAR-2 pathway. J Invest Dermatol. 2001;116(4):587–95.

    Article  CAS  PubMed  Google Scholar 

  48. Finkey MB, Herndon J, Stephens T, Appa Y. Soy moisturizer SPF15 improves dyschromia. J Am Acad Dermatol. 2005;52(3):P170.

    Google Scholar 

  49. Sah A, Stephens TJ, Kurtz ES. Topical acne treatment improves postacne postinflammatory hyperpigmentation (PIH) in skin of color. J Am Acad Dermatol. 2005;52(3):P25.

    Google Scholar 

  50. Hakozaki T, Minwalla L, Zhuang J, Chhoa M, Matsubara A, Miyamoto K, et al. The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br J Dermatol. 2002;147(1):20–31.

    Article  CAS  PubMed  Google Scholar 

  51. Bissett DL, Robinson LR, Raleigh PS, Miyamoto K, Hakozaki T, Li J, et al. Reduction in the appearance of facial hyperpigmentation by topical N-acetyl glucosamine. J Cosmet Dermatol. 2007;6(1):20–6.

    Article  PubMed  Google Scholar 

  52. Halder RM, Richards GM. Topical agents used in the management of hyperpigmentation. Skin Therapy Lett. 2004;9(6):1–3.

    CAS  PubMed  Google Scholar 

  53. Ennes S, Paschoalick R, Alchorne MMDA. A double-blind, comparative, placebo-controlled study of the efficacy and tolerability of 4% hydroquinone as a depigmenting agent in melasma. J Dermatolog Treat. 2000;11(3):173–9.

    Article  CAS  Google Scholar 

  54. Rendon M, Dryer L. Investigator-blinded, single-center study to evaluate the efficacy and tolerability of a 4% hydroquinone skin care system plus 0.02% tretinoin cream in mild-to-moderate melasma and photodamage. J Drugs Derm. 2016;15(4):466–75.

    Google Scholar 

  55. Simmons BJ, Griffith RD, Bray FN, Falto-Aizpurua LA, Nouri K. Exogenous ochronosis: a comprehensive review of the diagnosis, epidemiology, causes, and treatments. Am J Clin Dermatol. 2015;16(3):205–12.

    Article  PubMed  Google Scholar 

  56. Hoshaw RA, Zimmerman KG, Menter A. Ochronosislike pigmentation from hydroquinone bleaching creams in American blacks. Arch Dermatol. 1985;121(1):105–8.

    Article  CAS  PubMed  Google Scholar 

  57. Andersen FA, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, et al. Final amended safety assessment of hydroquinone as used in cosmetics. Int J Toxicol. 2010;29(6 Suppl):274s–87.

    Article  CAS  PubMed  Google Scholar 

  58. Nordlund JJ, Grimes PE, Ortonne JP. The safety of hydroquinone. J Eur Acad Dermatol Venereol. 2006;20(7):781–7.

    Article  CAS  PubMed  Google Scholar 

  59. Kari FW, Bucher J, Eustis SL, Haseman JK, Huff JE. Toxicity and carcinogenicity of hydroquinone in F344/N rats and B6C3F1 mice. Food Chem Toxicol. 1992;30(9):737–47.

    Article  CAS  PubMed  Google Scholar 

  60. Ortonne JP. Retinoic acid and pigment cells: a review of in-vitro and in-vivo studies. Br J Dermatol. 1992;127(Suppl 41):43–7.

    Article  PubMed  Google Scholar 

  61. Kimbrough-Green CK, Griffiths CE, Finkel LJ, Hamilton TA, Bulengo-Ransby SM, Ellis CN, et al. Topical retinoic acid (tretinoin) for melasma in black patients: a vehicle-controlled clinical trial. Arch Dermatol. 1994;130(6):727–33.

    Article  CAS  PubMed  Google Scholar 

  62. Callender VD. Acne in ethnic skin: special considerations for therapy. Dermatol Ther. 2004;17(2):184–95.

    Article  PubMed  Google Scholar 

  63. Jacyk WK, Mpofu P. Adapalene gel 0.1% for topical treatment of acne vulgaris in African patients. Cutis. 2001;68(4 Suppl):48–54.

    Google Scholar 

  64. Rivas S, Pandya AG. Treatment of melasma with topical agents, peels and lasers: an evidence-based review. Am J Clin Dermatol. 2013;14(5):359–76.

    Article  PubMed  Google Scholar 

  65. Grimes P, Callender V. Tazarotene cream for postinflammatory hyperpigmentation and acne vulgaris in darker skin: a double-blind, randomized, vehicle-controlled study. Cutis. 2006;77(1):45–50.

    PubMed  Google Scholar 

  66. Taylor SC, Torok H, Jones T, Lowe N, Rich P, Tschen E, et al. Efficacy and safety of a new triple-combination agent for the treatment of facial melasma. Cutis. 2003;72(1):67–72.

    PubMed  Google Scholar 

  67. Torok HM, Jones T, Rich P, Smith S, Tschen E. Hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%: a safe and efficacious 12-month treatment for melasma. Cutis. 2005;75(1):57–62.

    PubMed  Google Scholar 

  68. Torok HM. A comprehensive review of the long-term and short-term treatment of melasma with a triple combination cream. Am J Clin Dermatol. 2006;7(4):223–30.

    Article  PubMed  Google Scholar 

  69. Nguyen QH, Bui TP. Azelaic acid: pharmacokinetic and pharmacodynamic properties and its therapeutic role in hyperpigmentary disorders and acne. Int J Dermatol. 1995;34(2):75–84.

    Article  CAS  PubMed  Google Scholar 

  70. Breathnach AS. Melanin hyperpigmentation of skin: melasma, topical treatment with azelaic acid, and other therapies. Cutis. 1996;57(1 Suppl):36–45.

    CAS  PubMed  Google Scholar 

  71. Lowe NJ, Rizk D, Grimes P, Billips M, Pincus S. Azelaic acid 20% cream in the treatment of facial hyperpigmentation in darker-skinned patients. Clin Ther. 1998;20(5):945–59.

    Article  CAS  PubMed  Google Scholar 

  72. Balina LM, Graupe K. The treatment of melasma. 20% azelaic acid versus 4% hydroquinone cream. Int J Dermatol. 1991;30(12):893–5.

    Article  CAS  PubMed  Google Scholar 

  73. Verallo-Rowell VM, Verallo V, Graupe K, Lopez-Villafuerte L, Garcia-Lopez M. Double-blind comparison of azelaic acid and hydroquinone in the treatment of melasma. Acta Derm Venereol. 1989;143(Suppl):58–61.

    CAS  Google Scholar 

  74. Draelos ZD. The combination of 2% 4-hydroxyanisole (mequinol) and 0.01% tretinoin effectively improves the appearance of solar lentigines in ethnic groups. J Cosmet Dermatol. 2006;5(3):239–44.

    Article  PubMed  Google Scholar 

  75. Lim JT. Treatment of melasma using kojic acid in a gel containing hydroquinone and glycolic acid. Dermatol Surg. 1999;25(4):282–4.

    Article  CAS  PubMed  Google Scholar 

  76. Kameyama K, Sakai C, Kondoh S, Yonemoto K, Nishiyama S, Tagawa M, et al. Inhibitory effect of magnesium L-ascorbyl-2-phosphate (VC-PMG) on melanogenesis in vitro and in vivo. J Am Acad Dermatol. 1996;34(1):29–33.

    Article  CAS  PubMed  Google Scholar 

  77. Badreshia-Bansal S, Draelos ZD. Insight into skin lightening cosmeceuticals for women of color. J Drugs Derm. 2007;6(1):32–9.

    Google Scholar 

  78. Kimball AB, Kaczvinsky JR, Li J, Robinson LR, Matts PJ, Berge CA, et al. Reduction in the appearance of facial hyperpigmentation after use of moisturizers with a combination of topical niacinamide and N-acetyl glucosamine: results of a randomized, double-blind, vehicle-controlled trial. Br J Dermatol. 2010;162(2):435–41.

    Article  CAS  PubMed  Google Scholar 

  79. Briganti S, Camera E, Picardo M. Chemical and instrumental approaches to treat hyperpigmentation. Pigment Cell Res. 2003;16(2):101–10.

    Article  PubMed  Google Scholar 

  80. Choi S, Lee SK, Kim JE, Chung MH, Park YI. Aloesin inhibits hyperpigmentation induced by UV radiation. Clin Exp Dermatol. 2002;27(6):513–5.

    Article  CAS  PubMed  Google Scholar 

  81. Ando H, Ryu A, Hashimoto A, Oka M, Ichihashi M. Linoleic acid and alpha-linolenic acid lightens ultraviolet-induced hyperpigmentation of the skin. Arch Dermatol Res. 1998;290(7):375–81.

    Article  CAS  PubMed  Google Scholar 

  82. Dahl A, Yatskayer M, Raab S, Oresajo C. Tolerance and efficacy of a product containing ellagic and salicylic acids in reducing hyperpigmentation and dark spots in comparison with 4% hydroquinone. J Drugs Derm. 2013;12(1):52–8.

    CAS  Google Scholar 

  83. Ryu JH, Seok JK, An SM, Baek JH, Koh JS, Boo YC. A study of the human skin-whitening effects of resveratryl triacetate. Arch Dermatol Res. 2015;307(3):239–47.

    Article  CAS  PubMed  Google Scholar 

  84. Huh SY, Shin JW, Na JI, Huh CH, Youn SW, Park KC. Efficacy and safety of liposome-encapsulated 4-n-butylresorcinol 0.1% cream for the treatment of melasma: a randomized controlled split-face trial. J Dermatol. 2010;37(4):311–5.

    Article  CAS  PubMed  Google Scholar 

  85. Malek J, Chedraoui A, Nikolic D, Barouti N, Ghosn S, Abbas O. Successful treatment of hydroquinone-resistant melasma using topical methimazole. Dermatol Ther. 2013;26(1):69–72.

    Article  PubMed  Google Scholar 

  86. Lehraiki A, Abbe P, Cerezo M, Rouaud F, Regazzetti C, Chignon-Sicard B, et al. Inhibition of melanogenesis by the antidiabetic metformin. J Invest Dermatol. 2014;134(10):2589–97.

    Article  CAS  PubMed  Google Scholar 

  87. Roberts WE. Chemical peeling in ethnic/dark skin. Dermatol Ther. 2004;17(2):196–205.

    Article  PubMed  Google Scholar 

  88. Quarles FN, Brody H, Johnson BA, Badreshia S. Chemical peels in richly pigmented patients. Dermatol Ther. 2007;20(3):147–8.

    Article  PubMed  Google Scholar 

  89. Stratigos AJ, Katsambas AD. Optimal management of recalcitrant disorders of hyperpigmentation in dark-skinned patients. Am J Clin Dermatol. 2004;5(3):161–8.

    Article  PubMed  Google Scholar 

  90. Spencer JM. Microdermabrasion. Am J Clin Dermatol. 2005;6(2):89–92.

    Article  PubMed  Google Scholar 

  91. El-Domyati M, Hosam W, Abdel-Azim E, Abdel-Wahab H, Mohamed E. Microdermabrasion: a clinical, histometric, and histopathologic study. J Cosmet Dermatol. 29 June 2016 [epub before print].

    Google Scholar 

  92. Bhalla M, Thami GP. Microdermabrasion: reappraisal and brief review of literature. Dermatol Surg. 2006;32(6):809–14.

    CAS  PubMed  Google Scholar 

  93. Shim EK, Barnette D, Hughes K, Greenway HT. Microdermabrasion: a clinical and histopathologic study. Dermatol Surg. 2001;27(6):524–30.

    CAS  PubMed  Google Scholar 

  94. Kauvar AN. Successful treatment of melasma using a combination of microdermabrasion and Q-switched Nd:YAG lasers. Lasers Surg Med. 2012;44(2):117–24.

    Article  PubMed  Google Scholar 

  95. Fabbrocini G, De Vita V, Fardella N, Pastore F, Annunziata MC, Mauriello MC, et al. Skin needling to enhance depigmenting serum penetration in the treatment of melasma. Plast Surg Int. 2011;2011:158241.

    CAS  PubMed  PubMed Central  Google Scholar 

  96. Lima Ede A. Microneedling in facial recalcitrant melasma: report of a series of 22 cases. An Bras Dermatol. 2015;90(6):919–21.

    Article  PubMed Central  Google Scholar 

  97. Budamakuntla L, Loganathan E, Suresh DH, Shanmugam S, Suryanarayan S, Dongare A, et al. A randomised, open-label, comparative study of tranexamic acid microinjections and tranexamic acid with microneedling in patients with melasma. J Cutan Aesthet Surg. 2013;6(3):139–43.

    Article  PubMed  PubMed Central  Google Scholar 

  98. Cohen BE, Elbuluk N. Microneedling in skin of color: a review of uses and efficacy. J Am Acad Dermatol. 2016;74(2):348–55.

    Article  PubMed  Google Scholar 

  99. Arora P, Sarkar R, Garg VK, Arya L. Lasers for treatment of melasma and post-inflammatory hyperpigmentation. J Cutan Aesthet Surg. 2012;5(2):93.

    Article  PubMed  PubMed Central  Google Scholar 

  100. Vashi NA. Cosmetic interventions for dyschromia: lasers. Aestheticians J. 2014;4(5):16–20.

    Google Scholar 

  101. Lee HC, Thng TG, Goh CL. Oral tranexamic acid (TA) in the treatment of melasma: a retrospective analysis. J Am Acad Dermatol. 2016;75(2):385–92.

    Article  CAS  PubMed  Google Scholar 

  102. Tse TW, Hui E. Tranexamic acid: an important adjuvant in the treatment of melasma. J Cosmet Dermatol. 2013;12(1):57–66.

    Article  PubMed  Google Scholar 

  103. Zhu H, Yang X. The clinical study of acidum tranexamicum on melasma. Pharm Prog. 2001;3:178–81.

    Google Scholar 

  104. Wu S, Shi H, Wu H, Yan S, Guo J, Sun Y, et al. Treatment of melasma with oral administration of tranexamic acid. Aesthetic Plast Surg. 2012;36(4):964–70.

    Article  PubMed  Google Scholar 

  105. Fisk WA, Agbai O, Lev-Tov HA, Sivamani RK. The use of botanically derived agents for hyperpigmentation: a systematic review. J Am Acad Dermatol. 2014;70(2):352–65.

    Article  CAS  PubMed  Google Scholar 

  106. Handog EB, Galang DA, de Leon-Godinez MA, Chan GP. A randomized, double-blind, placebo-controlled trial of oral procyanidin with vitamins A, C, E for melasma among Filipino women. Int J Dermatol. 2009;48(8):896–901.

    Article  PubMed  Google Scholar 

  107. Ni Z, Mu Y, Gulati O. Treatment of melasma with Pycnogenol. Phytother Res. 2002;16(6):567–71.

    Article  CAS  PubMed  Google Scholar 

  108. Ahmed AM, Lopez I, Perese F, Vasquez R, Hynan LS, Chong B, et al. A randomized, double-blinded, placebo-controlled trial of oral Polypodium leucotomos extract as an adjunct to sunscreen in the treatment of melasma. JAMA Dermatol. 2013;149(8):981–3.

    Article  PubMed  Google Scholar 

  109. Martin L, Caperton C, H W-L, editors. A randomized double-blind placebo controlled study evaluating the effectiveness and tolerability of oral Polypodium leucotomos in patients with melasma. American Academy of Dermatology Annual Meeting; March 15–20, 2012; San Diego, California.

    Google Scholar 

  110. Middelkamp-Hup MA, Pathak MA, Parrado C, Garcia-Caballero T, Rius-Diaz F, Fitzpatrick TB, et al. Orally administered Polypodium leucotomos extract decreases psoralen-UVA-induced phototoxicity, pigmentation, and damage of human skin. J Am Acad Dermatol. 2004;50(1):41–9.

    Article  PubMed  Google Scholar 

  111. Yamakoshi J, Otsuka F, Sano A, Tokutake S, Saito M, Kikuchi M, et al. Lightening effect on ultraviolet-induced pigmentation of guinea pig skin by oral administration of a proanthocyanidin-rich extract from grape seeds. Pigment Cell Res. 2003;16(6):629–38.

    Article  CAS  PubMed  Google Scholar 

  112. Yamakoshi J, Sano A, Tokutake S, Saito M, Kikuchi M, Kubota Y, et al. Oral intake of proanthocyanidin-rich extract from grape seeds improves chloasma. Phytother Res. 2004;18(11):895–9.

    Article  PubMed  Google Scholar 

  113. Malathi M, Thappa DM. Systemic skin whitening/lightening agents: what is the evidence? Indian J Dermatol Venereol Leprol. 2013;79(6):842–6.

    Article  PubMed  Google Scholar 

  114. Food and Drug Administration. DOH-FDA Advisory No. 2011–004: Safety on the off-label use of glutathione solution for injection (IV). Department of Health, editor. Republic of the Philippines 2011.

    Google Scholar 

  115. Wenczl E, Van der Schans GP, Roza L, Kolb RM, Timmerman AJ, Smit NP, et al. (Pheo)melanin photosensitizes UVA-induced DNA damage in cultured human melanocytes. J Invest Dermatol. 1998;111(4):678–82.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Boston University Medical Center, 609 Albany Street, J-205, Boston, MA, 02118, USA

    Judy Cheng

  2. Department of Dermatology, Center for Ethnic Skin, Boston University, Boston, MA, USA

    Neelam A. Vashi

  3. Boston University School of Medicine, Boston Medical Center, Boston, MA, USA

    Neelam A. Vashi

Authors
  1. Judy Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Neelam A. Vashi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Neelam A. Vashi .

Editor information

Editors and Affiliations

  1. Department of Dermatology, Center for Ethnic Skin, Boston University, Boston, Massachusetts, USA

    Neelam A. Vashi

  2. University of California, San Francisco, San Francisco, California, USA

    Howard I. Maibach

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Cheng, J., Vashi, N.A. (2017). Treatment Strategies for Hyperpigmentation. In: Vashi, N., Maibach, H. (eds) Dermatoanthropology of Ethnic Skin and Hair. Springer, Cham. https://doi.org/10.1007/978-3-319-53961-4_23

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-53961-4_23

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-53960-7

  • Online ISBN: 978-3-319-53961-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation